4basebio (LON:4BB) Stock Price Down 5.5% – Here’s Why

4basebio PLC (LON:4BB) shares fell 5.5% on Thursday . The company traded as low as GBX 519.75 and last traded at GBX 519.75. Approximately 2 shares traded hands during trading, a decline of 100% from the average daily volume of 1,415 shares. The stock had previously closed at GBX 550.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada dropped their price objective on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of GBX 1,400.

4basebio Stock Down 5.5%

The company has a market cap of £80.48 million, a price-to-earnings ratio of -4.77 and a beta of 1.09. The business has a 50-day simple moving average of GBX 523.47 and a two-hundred day simple moving average of GBX 525.29. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

4basebio (LON:4BB) last issued its quarterly earnings data on Wednesday, May 20th. The company reported GBX (1.09) earnings per share for the quarter. The company had revenue of GBX 169 million during the quarter. As a group, equities analysts forecast that 4basebio PLC will post -3.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Amy Walker bought 1,863 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of GBX 509 per share, with a total value of £9,482.67. 12.08% of the stock is owned by company insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.